|
1
|
Johnstone RW, Frew AJ and Smyth MJ: The
TRAIL apoptotic pathway in cancer onset, progression and therapy.
Nat Rev Cancer. 8:782–798. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Koschny R, Walczak H and Ganten TM: The
promise of TRAIL - potential and risks of a novel anticancer
therapy. J Mol Med (Berl). 85:923–935. 2007. View Article : Google Scholar
|
|
3
|
Walczak H, Miller RE, Ariail K, et al:
Tumoricidal activity of tumor necrosis factor-related
apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gonzalvez F and Ashkenazi A: New insights
into apoptosis signaling by Apo2L/TRAIL. Oncogene. 29:4752–4765.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shi Y: Mechanisms of caspase activation
and inhibition during apoptosis. Mol Cell. 9:459–470. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ashkenazi A, Holland P and Eckhardt SG:
Ligand-based targeting of apoptosis in cancer: the potential of
recombinant human apoptosis ligand 2/Tumor necrosis factor-related
apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol.
26:3621–3630. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pan Y, Xu R, Peach M, et al: Evaluation of
pharmacodynamic biomarkers in a Phase 1a trial of dulanermin
(rhApo2L/TRAIL) in patients with advanced tumours. Br J Cancer.
105:1830–1838. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wiezorek J, Holland P and Graves J: Death
receptor agonists as a targeted therapy for cancer. Clin Cancer
Res. 16:1701–1708. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dimberg LY, Anderson CK, Camidge R,
Behbakht K, Thorburn A and Ford HL: On the TRAIL to successful
cancer therapy? Predicting and counteracting resistance against
TRAIL-based therapeutics. Oncogene. 32:1341–1350. 2013. View Article : Google Scholar
|
|
10
|
Zhang L and Fang B: Mechanisms of
resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther.
12:228–237. 2005. View Article : Google Scholar
|
|
11
|
Jin Z, McDonald ER III, Dicker DT and
El-Deiry WS: Deficient tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) death receptor transport to the
cell surface in human colon cancer cells selected for resistance to
TRAIL-induced apoptosis. J Biol Chem. 279:35829–35839. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim HS, Lee JW, Soung YH, et al:
Inactivating mutations of caspase-8 gene in colorectal carcinomas.
Gastroenterology. 125:708–715. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hernandez A, Wang QD, Schwartz SA and
Evers BM: Sensitization of human colon cancer cells to
TRAIL-mediated apoptosis. J Gastrointest Surg. 5:56–65. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Burns TF and El-Deiry WS: Identification
of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive
colon carcinoma cell line SW480 using a genetic approach. J Biol
Chem. 276:37879–37886. 2001.PubMed/NCBI
|
|
15
|
Cummins JM, Kohli M, Rago C, Kinzler KW,
Vogelstein B and Bunz F: X-linked inhibitor of apoptosis protein
(XIAP) is a nonredundant modulator of tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human
cancer cells. Cancer Res. 64:3006–3008. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Murphy JJ, Heptinstall S and Mitchell JR:
Randomised double-blind placebo-controlled trial of feverfew in
migraine prevention. Lancet. 2:189–192. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hehner SP, Heinrich M, Bork PM, et al:
Sesquiterpene lactones specifically inhibit activation of NF-kappa
B by preventing the degradation of I kappa B-alpha and I kappa
B-beta. J Biol Chem. 273:1288–1297. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lyss G, Knorre A, Schmidt TJ, Pahl HL and
Merfort I: The anti-inflammatory sesquiterpene lactone helenalin
inhibits the transcription factor NF-kappaB by directly targeting
p65. J Biol Chem. 273:33508–33516. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang S, Ong CN and Shen HM: Involvement
of proapoptotic Bcl-2 family members in parthenolide-induced
mitochondrial dysfunction and apoptosis. Cancer Lett. 211:175–188.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim SL, Trang KT, Kim SH, et al:
Parthenolide suppresses tumor growth in a xenograft model of
colorectal cancer cells by inducing mitochondrial dysfunction and
apoptosis. Int J Oncol. 41:1547–1553. 2012.PubMed/NCBI
|
|
21
|
Wen J, You KR, Lee SY, Song CH and Kim DG:
Oxidative stress-mediated apoptosis. The anticancer effect of the
sesquiterpene lactone parthenolide. J Biol Chem. 277:38954–38964.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang S, Ong CN and Shen HM: Critical
roles of intracellular thiols and calcium in parthenolide-induced
apoptosis in human colorectal cancer cells. Cancer Lett.
208:143–153. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pajak B, Gajkowska B and Orzechowski A:
Molecular basis of parthenolide-dependent proapoptotic activity in
cancer cells. Folia Histochem Cytobiol. 46:129–135. 2008.PubMed/NCBI
|
|
24
|
Dai Y, Guzman ML, Chen S, et al: The NF
(Nuclear factor)-kappaB inhibitor parthenolide interacts with
histone deacetylase inhibitors to induce MKK7/JNK1-dependent
apoptosis in human acute myeloid leukaemia cells. Br J Haematol.
151:70–83. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun Y, St Clair DK, Xu Y, Crooks PA and St
Clair WH: A NADPH oxidase-dependent redox signaling pathway
mediates the selective radiosensitization effect of parthenolide in
prostate cancer cells. Cancer Res. 70:2880–2890. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sobota R, Szwed M, Kasza A, Bugno M and
Kordula T: Parthenolide inhibits activation of signal transducers
and activators of transcription (STATs) induced by cytokines of the
IL-6 family. Biochem Biophys Res Commun. 267:329–333. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim SL, Lee ST, Trang KT, et al:
Parthenolide exerts inhibitory effects on angiogenesis through the
downregulation of VEGF/VEGFRs in colorectal cancer. Int J Mol Med.
33:1261–1267. 2014.PubMed/NCBI
|
|
28
|
Carlisi D, D’Anneo A, Angileri L, et al:
Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by
inducing the expression of death receptors through inhibition of
STAT3 activation. J Cell Physiol. 226:1632–1641. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fang LJ, Shao XT, Wang S, Lu GH, Xu T and
Zhou JY: Sesquiterpene lactone parthenolide markedly enhances
sensitivity of human A549 cells to low-dose oxaliplatin via
inhibition of NF-kappaB activation and induction of apoptosis.
Planta Med. 76:258–264. 2010. View Article : Google Scholar
|
|
30
|
Gao ZW, Zhang DL and Guo CB: Paclitaxel
efficacy is increased by parthenolide via nuclear factor-kappaB
pathways in in vitro and in vivo human non-small cell lung cancer
models. Curr Cancer Drug Targets. 10:705–715. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yun BR, Lee MJ, Kim JH, Kim IH, Yu GR and
Kim DG: Enhancement of parthenolide-induced apoptosis by a
PKC-alpha inhibition through heme oxygenase-1 blockage in
cholangiocarcinoma cells. Exp Mol Med. 42:787–797. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee CS, Kim YJ, Lee SA, Myung SC and Kim
W: Combined effect of Hsp90 inhibitor geldanamycin and parthenolide
via reactive oxygen species-mediated apoptotic process on
epithelial ovarian cancer cells. Basic Clin Pharmacol Toxicol.
111:173–181. 2012.PubMed/NCBI
|
|
33
|
Yip-Schneider MT, Nakshatri H, Sweeney CJ,
Marshall MS, Wiebke EA and Schmidt CM: Parthenolide and sulindac
cooperate to mediate growth suppression and inhibit the nuclear
factor-kappa B pathway in pancreatic carcinoma cells. Mol Cancer
Ther. 4:587–594. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim SL, Kim SH, Trang KT, et al:
Synergistic antitumor effect of 5-fluorouracil in combination with
parthenolide in human colorectal cancer. Cancer Lett. 335:479–486.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fulda S and Debatin KM: Death receptor
signaling in cancer therapy. Curr Med Chem Anticancer Agents.
3:253–262. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bates RC, Edwards NS, Burns GF and Fisher
DE: A CD44 survival pathway triggers chemoresistance via lyn kinase
and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer
Res. 61:5275–5283. 2001.PubMed/NCBI
|
|
38
|
Woynarowski JM and Konopa J: Inhibition of
DNA biosynthesis in HeLa cells by cytotoxic and antitumor
sesquiterpene lactones. Mol Pharmacol. 19:97–102. 1981.PubMed/NCBI
|
|
39
|
Nakshatri H, Rice SE and Bhat-Nakshatri P:
Antitumor agent parthenolide reverses resistance of breast cancer
cells to tumor necrosis factor-related apoptosis-inducing ligand
through sustained activation of c-Jun N-terminal kinase. Oncogene.
23:7330–7344. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Vasilevskaya IA and O’Dwyer PJ:
17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance
in colon cancer cell lines. Biochem Pharmacol. 70:580–589. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Galligan L, Longley DB, McEwan M, Wilson
TR, McLaughlin K and Johnston PG: Chemotherapy and TRAIL-mediated
colon cancer cell death: the roles of p53, TRAIL receptors, and
c-FLIP. Mol Cancer Ther. 4:2026–2036. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Saturno G, Valenti M, De Haven Brandon A,
et al: Combining trail with PI3 kinase or HSP90 inhibitors enhances
apoptosis in colorectal cancer cells via suppression of survival
signaling. Oncotarget. 4:1185–1198. 2013.PubMed/NCBI
|
|
43
|
Ashkenazi A and Herbst RS: To kill a tumor
cell: the potential of proapoptotic receptor agonists. J Clin
Invest. 118:1979–1990. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Eberle J, Fecker LF, Forschner T, Ulrich
C, Rowert-Huber J and Stockfleth E: Apoptosis pathways as promising
targets for skin cancer therapy. Br J Dermatol. 156(Suppl 3):
18–24. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pennarun B, Meijer A, de Vries EG,
Kleibeuker JH, Kruyt F and de Jong S: Playing the DISC: turning on
TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys
Acta. 1805:123–140. 2010.
|
|
46
|
Jung YH, Heo J, Lee YJ, Kwon TK and Kim
YH: Quercetin enhances TRAIL-induced apoptosis in prostate cancer
cells via increased protein stability of death receptor 5. Life
Sci. 86:351–357. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Prasad S, Ravindran J, Sung B, Pandey MK
and Aggarwal BB: Garcinol potentiates TRAIL-induced apoptosis
through modulation of death receptors and antiapoptotic proteins.
Mol Cancer Ther. 9:856–868. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kim YH, Lee DH, Jeong JH, Guo ZS and Lee
YJ: Quercetin augments TRAIL-induced apoptotic death: involvement
of the ERK signal transduction pathway. Biochem Pharmacol.
75:1946–1958. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Psahoulia FH, Drosopoulos KG, Doubravska
L, Andera L and Pintzas A: Quercetin enhances TRAIL-mediated
apoptosis in colon cancer cells by inducing the accumulation of
death receptors in lipid rafts. Mol Cancer Ther. 6:2591–2599. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sung B, Park B, Yadav VR and Aggarwal BB:
Celastrol, a triterpene, enhances TRAIL-induced apoptosis through
the down-regulation of cell survival proteins and up-regulation of
death receptors. J Biol Chem. 285:11498–11507. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Park MH, Jo M, Won D, Song HS, Song MJ and
Hong JT: Snake venom toxin from Vipera lebetina turanica sensitizes
cancer cells to TRAIL through ROS- and JNK-mediated upregulation of
death receptors and downregulation of survival proteins. Apoptosis.
17:1316–1326. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fernandes-Alnemri T, Litwack G and Alnemri
ES: CPP32, a novel human apoptotic protein with homology to
Caenorhabditis elegans cell death protein Ced-3 and mammalian
interleukin-1 beta-converting enzyme. J Biol Chem. 269:30761–30764.
1994.PubMed/NCBI
|
|
53
|
Teitz T, Wei T, Valentine MB, et al:
Caspase 8 is deleted or silenced preferentially in childhood
neuroblastomas with amplification of MYCN. Nat Med. 6:529–535.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mignotte B and Vayssiere JL: Mitochondria
and apoptosis. Eur J Biochem. 252:1–15. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Reed JC: Double identity for proteins of
the Bcl-2 family. Nature. 387:773–776. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
De Angelis PM, Stokke T, Thorstensen L,
Lothe RA and Clausen OP: Apoptosis and expression of Bax, Bcl-x,
and Bcl-2 apoptotic regulatory proteins in colorectal carcinomas,
and association with p53 genotype/phenotype. Mol Pathol.
51:254–261. 1998. View Article : Google Scholar
|
|
57
|
Maurer CA, Friess H, Buhler SS, et al:
Apoptosis inhibiting factor Bcl-xL might be the crucial member of
the Bcl-2 gene family in colorectal cancer. Dig Dis Sci.
43:2641–2648. 1998. View Article : Google Scholar
|
|
58
|
Rampino N, Yamamoto H, Ionov Y, et al:
Somatic frameshift mutations in the BAX gene in colon cancers of
the microsatellite mutator phenotype. Science. 275:967–969. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Sionov RV and Haupt Y: The cellular
response to p53: the decision between life and death. Oncogene.
18:6145–6157. 1999. View Article : Google Scholar : PubMed/NCBI
|
